Relazione sulla Remunerazione MolMed S.p.A.
MolMed receives IND clearance by the FDA to conduct a Phase III trial of TK for high-risk leukaemia in the United States
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text
1 - [Note: this notice is the English translation of the official version of the 102 notice which will be in Italian language]
MolMed now part of AGC Biologics | LinkedIn
Aptamer-Based Antibacterial and Antiviral Therapy against Infectious Diseases | Journal of Medicinal Chemistry
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHER
MolMed, viaggio nell'officina dei superfarmaci per le terapie geniche - Il Sole 24 ORE
MolMed: Contact Details and Business Profile
Sergio Signore (@signore_sergio) / Twitter
MolMed: AIFA approva commercializzazione Zalmoxis. Titolo vola in Borsa - Economia e Finanza - Repubblica.it
Will MolMed soon have its first Cell therapy on the Market?
Il 2019 è l'anno della svolta per MolMed - MilanoFinanza.it
Innovazione, la Borsa corre con plastica e super batteri - Corriere.it
Il gioiello biotech MolMed ai giapponesi. Inizia così lo shopping a Piazza Affari - Formiche.net
MolMed now part of AGC Biologics | LinkedIn
Molmed, l'Opa giapponese in bilico per golden power - ilGiornale.it
Press release issued by MolMed S.p.A. upon request of AGC Inc. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART
L'ok Ue fa volare Molmed (+11%) - MilanoFinanza.it
Molmed, la giapponese Agc supera il 50% in Opa - Il Sole 24 ORE
Voluntary Tender Offer launched by AGC Inc. on all ordinary shares of MolMed: the Board of Directors approves the Issuer's not
